Axcella Health Inc. (Nasdaq: AXLA), a biotechnology company pioneering the research and development of novel multifactorial interventions to address dysregulated metabolism and support health, today announced that the company will present two posters for two of its liver health-focused AXA candidates, AXA1665 and AXA1125 at the American Association for the Study of Liver Disease (AASLD) conference taking place November 8 - 12, 2019 in Boston, MA
October 1, 2019
· 5 min read